Recent developments in the management of secondary hyperparathyroidism

Kidney International

Volumn 59, Issue 3, 2001, Pages 1187-1201

  Goodman, William G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Calcimimetic agents; Calcitriol; Chronic renal failure; Hypercalcemia; Hyperphosphatemia; PTH; Vitamin D

Indexed keywords

CALCIUM CHANNEL STIMULATING AGENT; PARATHYROID HORMONE;

ADULT; ARTICLE; CALCIUM MOBILIZATION; CASE REPORT; FEMALE; GENETIC TRANSCRIPTION; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; HYPOCALCEMIA; KIDNEY DISEASE; PRIORITY JOURNAL; SARCOPLASMIC RETICULUM; SECONDARY HYPERPARATHYROIDISM;

EID: 0035092352     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2001.0590031187.x     Document Type: Article

References (80)

1. Hyperphosphatemia: Its consequences and treatment in patients with chronic renal disease
2. Pathogenesis of secondary hyperparathyroidism
3. Calcium acetate versus calcium carbonate as phosphate-binding agents in chronic haemodialysis
4. Calcium carbonate is an effective phosphate binder when dialysate calcium concentration is adjusted to control hypercalcemia
5. The effects of calcium carbonate as the sole phosphate binder in combination with low calcium dialysate and calcitriol therapy in chronic hemodialysis patients
6. Oral and parenteral calcitriol for the management of end-stage renal disease
7. Association of serum phosphorus and calcium × phosphorus product with mortality risk in chronic hemodialysis patients: A national study
8. Coronary artery calcification in young adults with end-stage renal disease undergoing dialysis
9. 2+-sensing receptor in primary and uremic secondary hyperparathyroidism
10. 3H-1,25-dihydroxyvitamin D in the parathyroid glands of patients with renal failure
11. Mechanisms underlying the regulation of parathyroid hormone secretion in vivo and in vitro
12. Conserved mechanism of negative gene regulation by extracellular calcium: Parathyroid hormone gene versus atrial natriuretic polypeptide gene
13. Direct effect of phosphorus on parathyroid hormone secretion from whole parathyroid glands in vitro
14. Phosphorus restriction prevents parathyroid gland growth: High phosphorus directly stimulates PTH secretion in vitro
15. Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure
16. RNA-protein binding and post-transcriptional regulation of parathyroid hormone gene expression by calcium and phosphate
17. Study of intestinal absorption of calcium in patients with renal failure
18. 3
19. 2D receptors are decreased in parathyroid glands from chronically uremic dogs
20. The hyperparathyroidism of chronic renal failure: A disorder of growth
21. Phosphorus restriction reverses hyperparathyroidism in uremia independent of changes in calcium and calcitriol
22. The effect of long-term intravenous calcitriol administration on parathyroid function in hemodialysis patients
23. Osteomalacia and bone disease arising from aluminum
24. Reduction of dietary phosphorus absorption by phosphorus binders: A theoretical in vitro and in vivo study
25. Calcium carbonate is an effective phosphate binder in patients with chronic renal failure undergoing dialysis
26. Dose dependency of calcium absorption: A comparison of calcium carbonate and calcium citrate
27. The treatment of uraemic hyperphosphataemia with calcium acetate and calcium carbonate: A comparative study
28. Calcium carbonate, an aluminum-free agent for control of hyperphosphatemia, hypocalcemia and hyperparathyroidism in uremia
29. Poly[allylamine hydrochloride] (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure
30. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium: Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients
31. Risk factors for renal osteodystrophy: A multivariant analysis
32. 3): An efficient and safe phosphate binder in haemodialysis patients?
33. Uremic small-artery disease with medial calcification and intimal hyperplasia (so-called calciphylaxis): A complication of chronic renal failure and benefit from parathyroidectomy
34. Calcium use increases risk of calciphylaxis: A case-control study
35. RenaGel, a novel calcium- and aluminum-free phosphate binder, inhibits phosphate absorption in normal volunteers
36. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone
37. Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients
38. Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients
39. Accelerated atherosclerosis in prolonged maintenance hemodialysis
40. Phosphate binders on iron basis: A new perspective?
41. Calcitriol, lanthanum carbonate, and other new phosphate binders in the management of renal osteodystrophy
42. Renal osteodystrophy
43. A dynamic bone disease with negative aluminum staining in predialysis patients: Prevalence and evolution after maintenance dialysis
44. Altered instantaneous and calcium-modulated oscillatory PTH secretion patterns in patients with secondary hyperparathyroidism
45. 3, in uremic man
46. 3 in normal man and patients with renal failure
47. The relationship between urinary calcium and calcium intake during treatment with calcitriol
48. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients
49. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure
50. Pharmakokinetics of calcitriol in CAPD/CCPD patients
51. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD
52. Selective vitamin D analogs and their therapeutic applications
53. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion
54. 22-Oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure
55. 3 by normal human peripheral monocytes
56. 2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia
57. Vitamin D analogues
58. 2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content
59. 2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis
60. Antirachitic activity of 1αhydroxyergocalciferol and 1α-hydroxcholecalciferol
61. 3 in the rat
62. 2 on calcium homeostasis in postmenopausal osteopenic women
63. 2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism
64. 2 (doxercalciferol) effectively and safely suppresses intact parathyroid hormone levels in hemodialysis patients with moderate to severe secondary hyperparathyroidism: Results of a multicenter double-blinded, placebo-controlled study
65. 3 pulse therapy
66. Calcium receptors as novel drug targets
67. NPS R-568 halts or reverses osteitis fibrosa in uremic rats
68. +2 receptor-dependent regulation of cellular functions
69. Negative regulatory elements in the human parathyroid hormone gene
70. Calcimimetics with potent and selective activity on the parathyroid calcium receptor
71. The calcimimetic NPS R-568 decreases plasma PTH in rats with mild and severe renal or dietary secondary hyperparathyroidism
72. Extracellular calcium-sensing receptor: Implications for calcium and magnesium handling in the kidney
73. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency: Control of parathyroid cell growth via a calcium receptor
74. A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure
75. Use of a calcimimetic agent to lower plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism
76. The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine
77. The extracellular animo-terminal region of the parathyroid hormone (PTH)/PTH-related peptide receptor determines the binding affinity for carboxyl-terminal fragments of PTH-(1-34)
78. Optimal correction of acidosis changes progression of dialysis osteodystrophy
79. Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptorablated mice
80. A mechanism of increased parathyroid hormone mRNA in experimental uremia: Roles of protein RNA binding in RNA degradation